Efficacy of ixekizumab in patients with plaque psoriasis, with and without previous exposure to biologic therapies: results at weeks 12 and 60 from UNCOVER-1

Gerdes S.; Korman N.; Wilhelm S.; Casillas M.; Zhao F.; Schacht A.; Dutronc Y.

首页> 外文期刊>Experimental dermatology >Efficacy of ixekizumab in patients with plaque psoriasis, with and without previous exposure to biologic therapies: results at weeks 12 and 60 from UNCOVER-1

【24h】

Efficacy of ixekizumab in patients with plaque psoriasis, with and without previous exposure to biologic therapies: results at weeks 12 and 60 from UNCOVER-1

机译：ixekizumab在斑块状银屑病患者中的疗效，无论是否曾接受过生物疗法：UNCOVER-1在第12周和第60周的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Experimental dermatology》 |2016年第3期|共1页
作者
Gerdes S.; Korman N.; Wilhelm S.; Casillas M.; Zhao F.; Schacht A.; Dutronc Y.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy of ixekizumab in patients with plaque psoriasis, with and without previous exposure to biologic therapies: results at weeks 12 and 60 from UNCOVER-1 [J] . Gerdes S., Korman N., Wilhelm S., Experimental dermatology . 2016,第3期

机译：ixekizumab在斑块状银屑病患者中的疗效，无论是否曾接受过生物疗法：UNCOVER-1在第12周和第60周的结果
2. Exposure‐Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis [J] . Chigutsa Emmanuel, Velez de Mendizabal Nieves, Chua Laiyi, The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2018,第11期

机译：曝光响应建模，以表征Ixekizumab血清药物浓度与中等至重度斑块牛皮癣患者的第12周的疗效反应的关系
3. A MODEL-BASED COMPARISON OF RESPONSE TO IXEKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS AFTER 12 AND 60 WEEKS OF TREATMENT. [J] . Chigutsa E., de Mendizabal N. V., Chua L., Clinical Pharmacology and Therapeutics . 2016,第Suppla1期

机译：在治疗12周和60周后中度重度斑块状牛皮癣的患者中，对依克舒单抗反应的基于模型的比较。
4. An Investigation into the Association and Prediction of Serious Infection in Patients on Biologic Therapies for Psoriasis [D] . Yiu, Zenas Z. N. 2018

机译：对牛皮癣生物疗法严重感染的关联与预测调查
5. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy safety and speed of response from a randomized double‐blinded trial [O] . A. Blauvelt, K. Papp, A. Gottlieb, -1

机译：ixekizumab与guselkumab在中度至重度斑块状牛皮癣患者中的头对头比较：一项随机双盲试验的12周疗效安全性和反应速度
6. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12 [O] . Alice B. Gottlieb, Daniel Saure, Stefan Wilhelm, 2020

机译：Ixekizumab与三个白细胞介素-33P19抑制剂的间接比较患者中度至重度斑块牛皮癣的患者 - 疗效结果，高达第12周

Efficacy of ixekizumab in patients with plaque psoriasis, with and without previous exposure to biologic therapies: results at weeks 12 and 60 from UNCOVER-1

著录项

相似文献

相关主题

期刊订阅